- Stifel initiated coverage of Surrozen Inc SRZN with a Buy rating and $19 price target.
- The regenerative medicine biotech started trading recently on NASDAQ via SPAC deal with Consonance-HFW Acquisition Corp.
- The price target represents an upside of 75%.
- The Company has two proprietary technology platforms that and it seeks to either activate or amplify wingless/integrated signaling to engender clinical benefit, analyst Dae Gon Ha writes.
- With lead programs SZN-1326 in moderate-severe ulcerative colitis and SZN-043 in severe alcoholic hepatitis, the analyst thinks proof of concept may emerge from Phase 1b patient studies.
- Price Action: SRZN stock is up 49.0% at $10.79 during the market session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Posted In: BiotechLong IdeasNewsHealth CarePrice TargetInitiationSmall CapAnalyst RatingsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
